Risk Factors and Machine Learning Model for Aminoglycines Related Acute Kidney Injury

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

8000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-07-01

Study Completion Date

2023-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Drug-induced acute kidney injury (D-AKI) can occur after treatment with aminoglycosides. Predicting the risk of D-AKI is important for a tailored prevention and palliation strategy. There are currently no studies to construct a model for predicting the risk of D-AKI associated with aminoglycosides. Therefore, the study aimed to develop a model to predict the risk of D-AKI that could be used in clinical practice. Clinical data of inpatients treated with aminoglycosides at the First Affiliated Hospital of Shandong First Medical University from January 2018 to December 2020, were collected. The primary endpoint was D-AKI, defined according to the 2012 Global Outcomes for Kidney Disease Improvement (KDIGO). Patient clinical information, including demographic information, admission and discharge information, disease history, medication information, and laboratory tests, was obtained through an in-hospital electronic medical record system. Independent risk factors associated with D-AKI will be screened by univariate and multifactorial analyses. Covariates with significant differences (P \< 0.05) were included in logistic regression models. The models were evaluated by the area under the curve (AUC) of the receiver operating characteristic curve (ROC) obtained by ten-fold cross-validation. Future studies are needed to test the application of this model in clinical practice to determine whether D-AKI in this setting can be predicted and mitigated.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Risk Factors and Machine Learning Model for Beta-Lactam Drugs Related Acute Kidney Injury

NCT05533606

Acute Kidney Injury Beta-Lactam Antibiotic Toxicity (Diagnosis)

COMPLETED

Risk Factors and Machine Learning Model for Diuretics Related Acute Kidney Injury

NCT05527054

Diuretic Toxicity Acute Kidney Injury

ACTIVE_NOT_RECRUITING

Deep Learning Model and Risk Factors for Tacrolimus-related Acute Kidney Injury

NCT06596798

AKI

ACTIVE_NOT_RECRUITING

Research on the Risk Warning Model and Prevention Strategies for Acute Kidney Injury Associated With Cyclosporine Based on Explainable Deep Neural Networks and Therapeutic Drug Monitoring

NCT06596811

AKI Therapeutic Drug Monitoring (TDM)

ACTIVE_NOT_RECRUITING

Risk Factors and Machine Learning Model for Proton Pump Inhibitor Related Acute Kidney Injury

NCT05533619

Proton Pump Inhibitor Acute Kidney Injury

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Aminoglycoside Toxicity Acute Kidney Injury

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

AKI Group

Aminoglycoside

Intervention Type DRUG

Inpatients using aminoglycoside

Non-AKI Group

Aminoglycoside

Intervention Type DRUG

Inpatients using aminoglycoside

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Aminoglycoside

Inpatients using aminoglycoside

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* All inpatients who used aminoglycosides during hospitalization
* Hospital stay ≥ 48h
* Age ≥18 years
* There are two or more blood creatinine tests during hospitalization

Exclusion Criteria

* Hospital stay \< 48h
* Age \<18 years
* Glomerular filtration rate (GFR) \< 30ml/min/1.73m2 within 48 hours after admission
* AKI was diagnosed on admission
* Less than two Scr test results during hospitalization
* The Scr values were always lower than 40 μmol/L during hospitalization
* Cases with incomplete medical history information

Minimum Eligible Age

18 Years

Maximum Eligible Age

100 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No